These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

9358 related articles for article (PubMed ID: 1966551)

  • 1. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. II. Mechanism of inhibition: the role of polymorphonuclear leukocytes.
    Neville ME; Pezzella KM; Schmidt K; Galbraith W; Ackerman N
    Cytokine; 1990 Nov; 2(6):456-63. PubMed ID: 1966551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo inhibition of tumor growth of B16 melanoma by recombinant interleukin 1 beta. I. Tumor inhibition parallels lymphocyte-activating factor activity of interleukin 1 beta proteins.
    Pezzella KM; Neville ME; Huang JJ
    Cytokine; 1990 Sep; 2(5):357-62. PubMed ID: 2103334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced antitumor efficacy in mice by combination treatment with interleukin-1 alpha and interferon-alpha.
    Brunda MJ; Wright RB; Luistro L; Harbison ML; Anderson TD; McIntyre KW
    J Immunother Emphasis Tumor Immunol; 1994 May; 15(4):233-41. PubMed ID: 8061895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor regression of human and murine melanoma after intratumoral injection of IL-12-encoding plasmid DNA in mice.
    Heinzerling L; Dummer R; Pavlovic J; Schultz J; Burg G; Moelling K
    Exp Dermatol; 2002 Jun; 11(3):232-40. PubMed ID: 12102662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumour effects of interleukin 1 beta: in vivo induction of immunity to B16 melanoma, a non-immunogenic tumour.
    Neville ME; Pezzella KM
    Cytokine; 1994 May; 6(3):310-7. PubMed ID: 8054488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
    Björkdahl O; Dohlsten M; Sjögren HO
    Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18.
    Nagai H; Hara I; Horikawa T; Fujii M; Kurimoto M; Kamidono S; Ichihashi M
    Cancer Invest; 2000; 18(3):206-13. PubMed ID: 10754989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of L-Arginine and L-NAME treatments on polymorphonuclear leukocytes and mononuclear cells influx during tumor growth.
    Reis OT; Raini JC; Coradi ST; Constantino DH
    Acta Cir Bras; 2009; 24(2):107-11. PubMed ID: 19377778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of periodontopathic bacteria on IL-1 and IL-1 inhibitor production by human polymorphonuclear neutrophils.
    Yamazaki K; Polak B; Bird PS; Gemmell E; Hara K; Seymour GJ
    Oral Microbiol Immunol; 1989 Dec; 4(4):193-8. PubMed ID: 2640313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential chemoimmunotherapy with cisplatin, interferon-beta and interleukin-2 inhibits the growth of B16-F1 melanoma in syngeneic mice.
    Kubo H; Matsumoto K; Funahashi M; Takagi H; Kitajima Y; Taniguchi S; Saida T
    Melanoma Res; 2000 Jun; 10(3):223-9. PubMed ID: 10890375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo elimination of CD25+ regulatory T cells leads to tumor rejection of B16F10 melanoma, when combined with interleukin-12 gene transfer.
    Nagai H; Horikawa T; Hara I; Fukunaga A; Oniki S; Oka M; Nishigori C; Ichihashi M
    Exp Dermatol; 2004 Oct; 13(10):613-20. PubMed ID: 15447721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism.
    Zheng LM; Ojcius DM; Garaud F; Roth C; Maxwell E; Li Z; Rong H; Chen J; Wang XY; Catino JJ; King I
    J Exp Med; 1996 Aug; 184(2):579-84. PubMed ID: 8760811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
    Wei H; Zheng X; Lou D; Zhang L; Zhang R; Sun R; Tian Z
    Mol Immunol; 2005 May; 42(9):1023-31. PubMed ID: 15829292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of therapeutic effect of recombinant tumor necrosis factor against B16 mouse melanoma by combination with recombinant interleukin 2.
    Urano K; Habu S; Nishimura T
    Cytokine; 1993 May; 5(3):224-9. PubMed ID: 8218934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
    Stagg J; Lejeune L; Paquin A; Galipeau J
    Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
    Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
    Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutrophil function in children with kwashiorkor.
    Schopfer K; Douglas SD
    J Lab Clin Med; 1976 Sep; 88(3):450-61. PubMed ID: 784886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effector mechanism of interleukin-1 beta at a distant site in the double grafted tumor system.
    Ebina T; Murata K
    Jpn J Cancer Res; 1991 Nov; 82(11):1292-8. PubMed ID: 1752785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endotoxin protection of rats from O2 toxicity: chemiluminescence of lung neutrophils.
    Berg JT; Smith RM
    Res Commun Chem Pathol Pharmacol; 1984 Jun; 44(3):461-76. PubMed ID: 6463368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 468.